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Abstract 
Background: Emerging evidence indicates that mesenchymal stromal cells (MSCs) isolated from different tissue 
sources may be used in vivo as tissue restorative agents. To date, there is no evidence, however, on migration and 
proliferation (“wound healing”) potential of different subsets of MSCs. The main goal of this study was therefore to 
compare the in vitro “wound healing” capacity of MSCs generated from positively selected CD271+ bone marrow 
mononuclear cells (CD271‑MSCs) and MSCs generated by plastic adherence (PA‑MSCs).
Methods: The in vitro model of wound healing (CytoSelect™ 24‑Well Wound Healing Assay) was used in order to 
compare the migration and proliferation potential of CD271‑MSCs and PA‑MSCs of passage 2 and 4 cultured in pres‑
ence or absence of growth factors or cytokines.
Results: CD271‑MSCs of both passages when compared to PA‑MSCs demonstrated a significantly higher potential 
to close the wound 12 and 24 h after initiation of the wound healing assay (P < 0.003 and P < 0.002, respectively). 
Noteworthy, the migration capacity of PA‑MSCs of second passage was significantly improved after stimulation with 
FGF‑2 (P < 0.02), PDGF‑BB (P < 0.006), MCP‑1 (P < 0.002) and IL‑6 (P < 0.03), whereas only TGF‑β enhanced significantly 
migration process of PA‑MSCs of P4 12 h after the treatment (P < 0.02). Interestingly, treatment of CD271‑MSCs of 
both passages with growth factors or cytokines did not affect their migratory potential.
Conclusions: Our in vitro data provide the first evidence that CD271‑MSCs are significantly more potent in “wound 
healing” than their counterparts PA‑MSCs.
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Background
Mesenchymal stromal cells (MSCs) are non-hemat-
opoietic multipotent cells which can be derived from 
bone marrow mononuclear cells [1], adipose tissue [2, 
3] or other tissues such as fetal liver, lungs, spleen [4, 5], 
amniotic fluid [6], cord blood [7], cord [8, 9], placenta 
[10, 11], endometrium [12] and dental pulp [13]. MSCs 
can be generated either by plastic adherence of progeni-
tor cells for MSCs (PA-MSCs) or by a positive selection 
with antibodies against cell surface antigens expressed by 
MSC-progenitor cells (D7-FIB, CD271, SSEA-4, GD2 and 
frizzled-9) [14–18]. CD271 (Low-affinity nerve growth 
factor receptor) antigen is present on human bone mar-
row cells and potentially defines a mesenchymal stromal 
cell (MSC) precursor subpopulation. Abundant evidence 
suggest that MSCs, isolated from different tissue sources, 
confer benefits in  vivo as tissue restorative agents [19]. 
Wound healing is a complex process that requires the 
coordinated interplay of extra cellular matrix, growth 
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factors, and cells. The presence of MSCs in normal skin 
and their critical role in wound healing suggests that the 
application of exogenous MSCs is a promising strategy 
to treat non-healing wounds resulting from trauma, dia-
betes, vascular insufficiency, and numerous other condi-
tions [20]. Bone marrow-derived mesenchymal stem cells 
(BM-MSCs) promote the healing of diabetic wounds due 
to increased re-epithelialization, cellularity, and angio-
genesis [21, 22]. These cells may participate directly in 
wound closure through progenitor cell proliferation and 
differentiation, as well as production of extracellular 
matrix (ECM) [23]. Several studies have shown that BM-
MSCs secrete a variety of cytokines and growth factors 
which are known to enhance normal wound healing [24–
27] including fibroblast growth factor-2 (FGF-2), epider-
mal growth factor (EGF), platelet-derived growth factor 
(PDGF), transforming growth factor beta (TGF-β) [28, 
29], hepatocyte growth factor (HGF), interleukin 6 (IL-
6), interleukin 8 (IL-8) [21] vascular endothelial growth 
factor (VEGF), stromal cell-derived factor (SDF) [27] 
and insulin-like growth factor-1 (IGF-1) [30–32]. Despite 
several in vivo studies which demonstrated the impact of 
MSCs on wound healing [33, 34], there is so far no evi-
dence on wound healing potential of different subsets 
of mesenchymal stromal cells. In this in  vitro study we 
focused on migration and proliferation (“wound healing”) 
capacity of MSCs generated from CD271+ bone mar-
row mononuclear cells (CD271-MSCs) and compared it 
to MSCs generated by plastic adherence (PA-MSCs). In 
addition, we evaluated the effect of different growth fac-
tors and cytokines in migration and proliferation poten-
tial of these cells.
Methods
Isolation of bone marrow mononuclear cells (BM‑MNCs)
Bone marrow aspirates were taken from the iliac crest of 
4 male healthy donors (age: 18–22 years) after informed 
consent and under a protocol approved by the Univer-
sity of Frankfurt Institutional Review Board. After dilu-
tion 1:2 in PBS, aspirates were centrifuged in 1.073 g/ml 
Ficoll density gradient in 700×g for 30 min. The enriched 
cells were collected from the interface, washed twice with 
PBS (PAA Laboratories GmbH, Austria) and centrifuged 
at 400×g for 10 min. A defined number of isolated BM-
MNCs were used for generation of PA-MSCs whereas the 
majority of them were used for enrichment of CD271+ 
cells.
Generation of CD271‑MSCs
CD271+ bone marrow mononuclear cells were isolated 
immune-magnetically using the MSC Research Tool 
Box–CD271 (LNGFR)-APC (Miltenyi Biotec GmbH), 
according to the manufacturer’s instructions. Highly 
purified bone marrow CD271+  mononuclear cells 
(1.25  ×  105/cm2) were seeded in T25 (25  cm2) culture 
flasks with vent caps in 6  ml DMEM low-glucose sup-
plemented with 10  % MSC-qualified fetal bovine serum 
(FBS) (GIBCO/Invitrogen, Darmstadt). The medium was 
changed after 7 days and later on every third day until the 
cells reached the confluence 70–80 % (10–14 day). MSCs 
generated in this way are referred to as CD271-MSCs 
throughout the manuscript. After this step the whole 
procedure was the same as for generation of PA-MSCs.
Generation of PA‑MSCs
To generate PA-MSCs, BM-MNCs were cultured in 
DMEM low-glucose supplemented with 10  % MSC-
qualified FBS. The cells were maintained at 37 °C in 95 % 
humidified atmosphere of 5 % CO2 for 72 h. Thereafter, the 
nonadherent cells were removed and fresh medium was 
added and changed every 2 or 3 days. The adherent spin-
dle-shaped cells were further cultured for 10–14 days until 
the cells reached about 70–80  % confluence. During this 
time the medium was changed every 3 days. To detach the 
MSCs the medium was removed and the cells were washed 
once with PBS. The cells were detached by exposure to 
trypsin TrypLE (Invitrogen) for 6  min at 37  °C, followed 
by tapping the dishes and the addition of culture medium. 
The cells were centrifuged then resuspended with medium 
and plated at a density of 2 × 103 MSCs/cm2. During cul-
ture the medium was changed every 3 days, and when the 
cells were confluent they were passaged. The cells were 
passaged three times, and cells from the second and fourth 
passage were used for experiment.
Colony forming unit‑fibroblast assay and expansion 
potential of CD271‑MSCs
To assess the clonogenic potential of positively selected 
CD271+ cells and BM-MNC, the CFU-F assay was per-
formed in 25 cm2 tissue culture flasks. For this purpose, 
2.5 × 105 BM-MNC/25 cm2, and 2.5 × 104 cells/25 cm2 
from the CD271-positive fraction were cultured for 
14  days. Colonies were stained with Giemsa solution 
(Merck, Darmstadt, Germany) and counted.
Immunophenotyping of CD271‑MSCs and PA‑MSCs
CD271-MSC and PA-MSC of different passages (from 
passage 1 to passage 4) were stained with fluorochrome-
conjugated mouse anti-human antibodies against follow-
ing antigens CD73, CD90, CD105, CD146, CD44, CD29, 
CD166, CD45, CD34 and CD14 and HLA-Class I and 
HLA Class II molecules and incubated at 4 °C for 30 min. 
After two wash steps with PBS + 0.2 % BSA the stained 
cells were analyzed on a FACSCalibur (Becton–Dickin-
son) equipped with Macintosh software for data analysis 
(CellQuest).
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Trilineage differentiation of MSCs
To induce differentiation of MSCs, specific medium 
was added to the cells according to the manufacturer’s 
instructions. Adipogenic differentiation was induced 
by NH Adipo Diff Medium (Miltenyi Biotec, Bergisch 
Gladbach). Osteogenic differentiation was achieved by 
NH OsteoDiff Medium (Miltenyi Biotec, Bergisch Glad-
bach), whereas chondrogenic differentiation was induced 
by NH ChondroDiff Medium (Miltenyi Biotec, Bergisch 
Gladbach). Each specific differentiation medium was 
changed every 2–3 days. Confirmation of differentiation 
of the cells to adipocytes, osteocytes and chondrocytes 
were performed by staining with Oil Red O staining solu-
tion, SIGMA FAST™ BCIP/NBT (5-bromo-4-chloro-
3-indolyl phosphate/nitro blue tetrazolium) tablets and 
Alcian blue-solution, respectively.
Wound healing assay
The wound healing process entails the migration and 
proliferation of different cells, including the MSCs. To 
compare the wound healing potential of CD271-MSCs 
and PA-MSCs, the second and fourth passage MSCs were 
cultured in DMEM containing 1  % FBS. To analyze the 
wound healing capacity, we used an in  vitro model of 
wound healing (CytoSelect™ 24-Well Wound Healing 
Assay) from the Cell Biolabs company (BIOCAT GmbH, 
Heidelberg, Germany). The CytoSelect™ 24-well Wound 
Healing Assay Kit consists of 2 × 24-well plates each con-
taining 12 proprietary treated plastic inserts. The inserts 
create a wound field with a defined gap of 0.9  mm for 
measuring the migration and proliferation rate of cells. In 
order to precisely find the same position at making the 
photographs, the center of each well was labeled before 
adding the cells.
Briefly, CD271-MSCs and PA-MSCs cell suspension 
containing 2 × 105 MSCs/ml DMEM with 1 % FBS was 
prepared. For optimal cell dispersion, 250 µL of cell sus-
pension was added on each side of the insert by care-
fully inserting the pipette tip through the open end of 
the insert (1  ×  105/well/500  µL). Cells were cultured 
until they formed a monolayer around the insert (24 h). 
Next day, the inserts were removed from the wells, leav-
ing a precise 0.9  mm open “wound field” between the 
cells. To assess how the “wound field” is affected by the 
cells itself, the wells were washed twice with PBS and 
then fulfilled with 500 µL of prepared medium. In addi-
tion, to see the effect of CD271-MSCs and PA-MSCs on 
wound closure in the presence of different growth factors 
(GFs) or cytokines, the wells were washed twice with PBS 
and then fulfilled with 500 µL of prepared medium with 
GFs/Cytokines (Table  1). In order to analyse migration 
capacity and not proliferation of the cells, the first pho-
tographs of the wounded area were taken at 0 h, after 6 
and after 12 h. After that period the cells were monitored 
for proliferation and photographs were made after 24 h. 
To measure the wound closure, we set a rectangle with a 
defined surface area and passed that on all photos of the 
other time points.
Estimation of percent closure was made after determi-
nation of the surface area of defined wound area (total 
surface area) and determination of the surface area of 
the migrated cells into the wounded area (migrated cell 
surface area): Total surface area  =  0.9  mm  ×  length; 
Migrated cell surface area  =  Length of cell migration 
(mm) × 2 × length, therefore:
Photographs were made with microscope Olympus IX71, 
whereas measurements were performed using Imaging 
software CellSens from Olympus manufacturer (Olym-
pus, Hamburg, Germany).
Percent closure (%) =Migrated cell surface area
/Totalsurfacearea× 100
Table 1 Growth factors and cytokines assessed for their effect on wound healing potential of MSCs
Growth factors and cytokines Final concentration Manufacturer
Human EGF 1 ng/ml Pepro Tech [GmbH‑Hamburg, Germany]
Human TGF‑β 5 ng/ml #
Human HGF 5 ng/ml #
Human FGF‑basic 20 ng/ml #
Human SDF‑1α 20 ng/ml #
Human MCP‑1 [MCAF] 20 ng/ml #
Human IL‑8 20 ng/ml #
Human IL‑6 10 ng/ml #
PDGF‑BB 20 ng/ml #
Rabbit anti‑human PDGF‑basic 2 µg/ml #
Page 4 of 9Latifi‑Pupovci et al. J Transl Med  (2015) 13:315 
Effect of some growth factors and cytokines in “wound 
healing” capacity of MSCs
To assess how different growth factors and cytokines 
affect migration capacity we compared the effects of fol-
lowing 10 growth factors/cytokines on migratory activ-
ity of CD271-MSCs and PA-MSCs: epidermal growth 
factor (EGF), transforming growth factor beta (TGFβ), 
hepatocyte growth factor (HGF), fibroblast growth factor 
2 (FGF-2), stromal-derived growth factor-1α (SDF-1α), 
monocyte chemotactic protein-1 (MCP-1), interleukin 8 
(IL-8), interleukin 6 (IL-6) and platelet-derived growth 
factor BB (PDGF-BB). To get additional insights into pos-
sible mechanisms involved in the migratory potential of 
MSCs we used antibodies against one of the key players 
in this process, platelet-derived growth factor BB (Ab-
PDGF- BB) (Table 1).
Statistical analysis
Data were analyzed by using standard statistical soft-
ware (GraphPad Prism Software, San Diego, CA, USA). 
Results are expressed as mean value  ±  standard devia-
tion. The statistical significance of values between two 
groups was evaluated by Student’s t test. Differences were 
considered significant when the P-value was 0.05 or less.
Results and discussion
Phenotype and trilineage differentiation potential 
of CD271‑MSCs and PA‑MSCs
Positively selected CD271+ BM-MNCs contained almost 
all progenitors for MSCs and therefore the number of 
CFU-Fs generated by using these cells was significantly 
higher than the number of generated CFU-Fs from 
non-selected BM-MNCs, as previously demonstrated 
[35] (Fig. 1a). Ex vivo expanded passage 2 and 4 CD271-
MSCs were negative for the hematopoietic cell markers 
CD14, CD45, hematopoietic stem cell marker CD34 as 
well as class II HLA-antigens (HLA-DR). However, they 
expressed typical mesenchymal cell surface markers, 
such as CD73, CD90, CD105 and HLA class I molecules 
(Fig.  1b). In addition, flow cytometry analysis demon-
strated that CD271 antigen is downregulated starting 
from passage 1 and is not detectable on the MSCs of 
either type during passage 2 (data not shown). Mesen-
chymal stromal cells generated through plastic adherence 
of unselected BM-MNCs (PA-MSCs) at passage 2 and 
4 expressed the same typical MSC markers at the same 
level as CD271-MSCs, either. Culture of the expanded 
CD271-MSC in tissue-specific media demonstrated that 




Fig. 1 Phenotype and trilineage potential of CD271‑MSCs. a Potential to generate CFU‑Fs. Positively selected CD271+ BM‑MNCs as well as 
non‑selected BM‑MNCs were incubated for 14 days. Next, generated CFU‑Fs were stained with Giemsa (blue spots on the bottom of tissue culture 
flasks) and then counted. Positively selected CD271+ BM‑MNCs gave rise to a significantly higher number of CFU‑Fs than non‑selected BM‑MNCs 
(P < 0.003). Results are persented as mean value ± standard error mean (n = 4). b Phenotype of CD271‑MSCs was determined at the end of P2 
and P4. Both types of MSCs studied revealed the same phenotype which is typcial for MSCs (negative for hematopoeitic markers and HLA‑DR and 
positive for CD73, CD90, CD105 and HLA‑Class I antigens). c Trilineage differentiation potential of both types of MSCs was evaluated by their culture 
in tissue‑specific media for adipocytes, osteoblasts and chondrocytes. Confirmation of trilineage differentiation of MSCs was performed by staining 
with Oil Red O staining solution for adipocytes, SIGMA FAST™ BCIP/NBT (5‑bromo‑4‑chloro‑3‑indolyl phosphate/nitro blue tetrazolium) tablets for 
osteoblasts and alcian blue solution for chondrocytes
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differentiate along adipogenic, osteogenic, and chondro-
genic lineages (Fig. 1c).
Evaluation of “wound closure” potential of MSCs
To analyse which types of MSCs (CD271-MSCs or PA-
MSCs) are better in “wound healing”, we assessed this 
potential in both types of MSCs in the absence (DMEM 
supplemented with 1  % FBS only: control) and in the 
presence of GFs/Cytokines. For this purpose, we com-
pared first the “wound healing” capacity between MSCs 
from different passages (P2 and P4) and thereafter we 
compared this potential between CD271-MSCs and PA-
MSCs. Having in mind that wound healing process is 
affected by both migration and proliferation of cells, we 
compared it after 6 and 12 h (as a result of migration) and 
after 24 h (as a result of proliferation) (Fig. 2).
MSCs of both types were cultured 24  h until a mon-
olayer formed at which time the inserts were removed 
to begin the wound healing assay. Cells were monitored 
under phase contrast (not shown) and followed by cell 
staining for determination of percent closure (0, 50, 75, 
and 100 %).
The effect of passages on the “wound healing” potential 
of MSCs
Before comparing “wound healing” capacity between 
CD271-MSCs and PA-MSCs, we asked whether the 
number of passages may affect this process. Comparative 
analysis of the data demonstrated that CD271-MSCs of 
passage 4 were significantly more effective than CD271-
MSCs of passage 2 in closing the wound 12 h after start-
ing the wound healing assay (P  <  0.006). However, no 
Fig. 2 Schematic presentation of the estimation of wound healing. a Wound gap at the beginning of assay (0 h). b Start of CD271‑MSC migration 
and wound closure after 6 h. c Migration and proliferation of CD271‑MSCs 12 h after the start and d “Wound” closure 24 h later. To stain CD271‑MSCs 
closing the wound, culture medium was removed and replaced with 400 µL of Cell Stain Solution for each well. Then the cells were incubated for 
15 min at room temperature. After aspiration of staining solution, the cells were washed 3 times with deionized water and then were allowed to dry 
at room temperature (scale bars = 200 µm)
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differences in the “wound healing” potential between 
passage 2 and 4 of CD271-MSCs were observed six and 
24 h after starting the assay (Fig. 3a). In contrast, passage 
4 of PA-MSCs was significantly more efficient in closing 
the wound 12 and 24 h after starting the assay (P < 0.01 
and P < 0.03, respectively) (Fig. 3b).
CD271‑MSCs possess a higher “wound healing” potential 
than PA‑MSCs
In the current study we assessed the “wound healing” 
potential of CD271-MSCs and PA-MSCs both in the 
absence (DMEM supplemented with 1 % FCS only: con-
trol) and presence of GFs/Cytokines.
When compared “wound healing” capacity of CD271-
MSCs to PA-MSCs in the absence (DMEM supplemented 
with 1  % FCS) of GFs/Cytokines, CD271-MSCs of pas-
sage 2 demonstrated a significantly higher potential to 
close the wound 12 and 24 h after initiation of the wound 
healing assay (P < 0.003 and P < 0.002, respectively). No 
differences were observed in the first 6  h of the wound 
closure (Fig.  3c). However, the “wound healing” poten-
tial of CD271-MSCs of passage 4 was significantly higher 
compared to PA-MSCs of the same passage only 12  h 
after initiation of the assay (P  <  0.03) and no difference 
was observed for the time-points 6 and 24  h (Fig.  3d). 
Therefore, these data indicate that in particular CD271-
MSCs of passage 2 are superior to PA-MSCs in the first 
12  h of the healing process, demonstrating for the first 
time that these MSCs possess a higher migratory poten-
tial than PA-MSCs.
Effect of various growth factors and cytokines on in vitro 
migration and proliferation potential of MSCs at different 
passages
It is well-known that different growth factors and 
cytokines are able to enhance MSCs migration [36, 
37]. To date, however, there is no evidence on the 
effect of these molecules on migration potential of 
a b
c d
Fig. 3 Wound healing potential of CD271‑MSCs and PA‑MSCs without exogenously added cytokines. a Comparison of wound healing potential of 
CD271‑MSCs at passage 2 (P2) and 4 (P4). b Comparison of wound healing potential of PA‑MSCs at passage 2 and 4. c Comparison of wound heal‑
ing potential of PA‑MSCs with that of CD271‑MSCs at passage 2. d Comparison of wound healing potential of PA‑MSCs with that of CD271‑MSCs at 
passage 4. Results are presented as mean ± SD of 4 independently performed experiments. Statistical significance was evaluated by Student’s t test. 
Differences were considered significant when the P value was 0.05 or less
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a b
c d
Fig. 4 The effect of various growth factors and cytokines on wound healing potential of passage 2 and passage 4 of PA‑MSCs and CD271‑MSCs 
12 h after the assay initiation. a The effect of GFs/cytokines on potential of passage 2 PA‑MSCs in wound closure. b The effect of GFs/cytokines on 
potential of passage 4 PA‑MSCs in wound closure. c The effect of GFs/cytokines on potential of passage 2 CD271‑MSCs in wound closure. d The 
effect of GFs/cytokines on potential of passage 4 CD271‑MSCs in wound closure. The effects of EGF (1 ng/ml), TGF‑β (5 ng/ml), HGF (5 ng/ml), FGF‑2 
(20 ng/ml), SDF‑1α (20 ng/ml), PDGF‑BB (20 ng/ml), MCP‑1 (20 ng/ml), IL‑8 (20 ng/ml) and IL‑6 (10 ng/ml) on wound closure were examined using 
CytoSelect™ 24‑well Wound Healing Assay. Significant changes were assessed by using unpaired t test. Data are represented as mean ± SD of at 
least n = 2
a b
Fig. 5 Effect of individual growth factors/cytokines on in vitro migration/proliferation capacity of mesenchymal stromal cells at different passages. 
a Effect of FGF‑2 on different passages of PA‑MSCs 6, 12 and 24 h after initiation of the wound assay. b Effect of IL‑6 on different passages of CD271‑
MSCs 6, 12 and 24 h after initiation of the wound assay
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MSC-subsets. In this study we asked which growth fac-
tors and cytokines may affect migration of specific type 
of MSCs to “injured tissues” and their proliferation. 
Therefore, we compared the “wound healing” capacity 
of CD271-MSCs and PA-MSCs of passage 2 and 4 after 
their treatment with 10 different cytokines and growth 
factors. Our data show that compared to control, sev-
eral growth factors significantly enhance “wound heal-
ing” capacity of PA-MSCs but not that of CD271-MSCs. 
The migration capacity of second passage PA-MSCs was 
significantly improved 12  h after treatment with FGF-2 
(P < 0.02), PDGF-BB (P < 0.006), MCP-1 (P < 0.002) and 
IL-6 (P < 0.03) (Fig. 4a). TGF-β was the only cytokine that 
affected significantly the “wound healing” potential of 
passage 4 PA-MSCs 12 h after the treatment (P = 0.02) 
(Fig.  4b). These data are consistent with the findings of 
previous studies which demonstrated that MCP-1 [38] 
and PDGF-BB significantly enhanced migration of MSCs 
to the wounded site [39–41]. In addition, the effect of 
FGF-2 on MSC migration potential was also observed by 
other authors, who showed that MSCs are highly sensi-
tive to FGF-2 [41, 42]. This is in line also with the obser-
vation of Schmidt et al. [42] who reported that migratory 
capacity of MSCs increases much more in presence of 
FGF-2 than IL-6. However, in contrast to other authors, 
EGF, HGF, TGF-beta, SDF and IL-8 did not significantly 
enhanced migration potential of PA-MSCs, as previously 
reported [43–46].
In contrast, neither growth factors nor cytokines were 
able to improve migration capacity of the second passage 
CD271-MSCs. Similarly to second passage, migration 
capacity and healing potential of passage 4 CD271-MSCs 
was not affected by a 12 h treatment with growth factors 
or cytokines (Fig.  4d). The greater capacity of CD271-
MSCs to produce higher levels of cytokines than PA-
MSCs [35] may account for this non-responsiveness 
of these cells to exogenously added cytokines/growth 
factors.
To confirm that these effects of GFs/Cytokines are 
mediated via receptors, we used neutralizing PDGF-BB 
antibody and investigated migration of MSCs. We found 
that PA-MSCs migration stimulated by PDGF-BB (20 ng/
ml) was inhibited by this neutralizing antibody at 2  µg/
ml and this inhibition was significant on cells of passage 
2 (P  <  0.03) and passage 4 (P  <  0.04) (data not shown), 
without abolishing the complete effect of PDGF-BB. This 
effect was consistent with the findings of Ozaki et al. [37], 
who observed the same effect in the migration experi-
ments with rabbit MSCs. However, no changes were 
observed in the migratory capacity of CD271-MSCs 
after addition of the PDGF-BB antibody. Comparison of 
the effect of individual growth factors/cytokines on the 
“wound healing” capacity of MSCs at different passages 
demonstrated that only FGF-2 significantly increased 
“wound healing” potential of PA-MSCs of passage 4 com-
pared to the cells of the second passage 12 and 24 h after 
initiation of the wound assay (P =  0.006 and P < 0.008, 
respectively) (Fig. 5a). In contrast, IL-6 was the cytokine 
which significantly improved “wound healing” poten-
tial of CD271-MSCs of fourth passage when compared 
to the CD271-MSCs of P2, 6, 12 and 24 h after initiation 
of the wound assay (P  <  0.0003, P  <  0.03 and P  <  0.03, 
respectively) (Fig. 5b). This positive effect of IL-6 can be 
explained by the fact that CD271-MSCs produce signifi-
cantly lower levels of IL-6 than PA-MSCs, as shown in 
our previous report [35].
Conclusions
To the best of our knowledge, we show for the first time 
that during the wound closure, both CD271-MSCs and 
PA-MSCs of passage 4 were superior to MSCs of passage 
2. In addition, the CD271-MSCs demonstrated a signifi-
cantly higher “wound healing” potential than PA-MSCs, 
suggesting that they may be more effective in the treat-
ment of the wounds.
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